Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the sa...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-15315-8 |
| id |
doaj-bd4459e944254dc4845c521cfcab9cf4 |
|---|---|
| record_format |
Article |
| spelling |
doaj-bd4459e944254dc4845c521cfcab9cf42021-05-11T08:05:49ZengNature Publishing GroupNature Communications2041-17232020-03-0111111310.1038/s41467-020-15315-8Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä0Doga C. Gulhan1Julia Casado2Connor A. Jacobson3Huy Nguyen4Bose Kochupurakkal5Zoltan Maliga6Clarence Yapp7Yu-An Chen8Denis Schapiro9Yinghui Zhou10Julie R. Graham11Bruce J. Dezube12Pamela Munster13Sandro Santagata14Elizabeth Garcia15Scott Rodig16Ana Lako17Dipanjan Chowdhury18Geoffrey I. Shapiro19Ursula A. Matulonis20Peter J. Park21Sampsa Hautaniemi22Peter K. Sorger23Elizabeth M. Swisher24Alan D. D’Andrea25Panagiotis A. Konstantinopoulos26Dana-Farber Cancer InstituteHarvard Medical SchoolResearch Program in Systems Oncology, University of HelsinkiLaboratory of Systems Pharmacology, Harvard Medical SchoolDana-Farber Cancer InstituteDana-Farber Cancer InstituteLaboratory of Systems Pharmacology, Harvard Medical SchoolLaboratory of Systems Pharmacology, Harvard Medical SchoolLaboratory of Systems Pharmacology, Harvard Medical SchoolLaboratory of Systems Pharmacology, Harvard Medical SchoolTESARO: A GSK companyTESARO: A GSK companyTESARO: A GSK companyHelen Diller Family Comprehensive Cancer CenterBrigham and Women’s Hospital, Laboratory for Systems PharmacologyDepartment of Pathology, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Pathology, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Pathology, Brigham and Women’s Hospital, Harvard Medical SchoolDana-Farber Cancer InstituteDana-Farber Cancer InstituteDana-Farber Cancer InstituteDepartment of Biomedical Informatics, Harvard Medical SchoolResearch Program in Systems Oncology, University of HelsinkiLaboratory of Systems Pharmacology, Harvard Medical SchoolUniversity of WashingtonDana-Farber Cancer InstituteDana-Farber Cancer InstituteA Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the same patients and find potential predictive biomarkers of response to such combination therapy.https://doi.org/10.1038/s41467-020-15315-8 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Anniina Färkkilä Doga C. Gulhan Julia Casado Connor A. Jacobson Huy Nguyen Bose Kochupurakkal Zoltan Maliga Clarence Yapp Yu-An Chen Denis Schapiro Yinghui Zhou Julie R. Graham Bruce J. Dezube Pamela Munster Sandro Santagata Elizabeth Garcia Scott Rodig Ana Lako Dipanjan Chowdhury Geoffrey I. Shapiro Ursula A. Matulonis Peter J. Park Sampsa Hautaniemi Peter K. Sorger Elizabeth M. Swisher Alan D. D’Andrea Panagiotis A. Konstantinopoulos |
| spellingShingle |
Anniina Färkkilä Doga C. Gulhan Julia Casado Connor A. Jacobson Huy Nguyen Bose Kochupurakkal Zoltan Maliga Clarence Yapp Yu-An Chen Denis Schapiro Yinghui Zhou Julie R. Graham Bruce J. Dezube Pamela Munster Sandro Santagata Elizabeth Garcia Scott Rodig Ana Lako Dipanjan Chowdhury Geoffrey I. Shapiro Ursula A. Matulonis Peter J. Park Sampsa Hautaniemi Peter K. Sorger Elizabeth M. Swisher Alan D. D’Andrea Panagiotis A. Konstantinopoulos Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer Nature Communications |
| author_facet |
Anniina Färkkilä Doga C. Gulhan Julia Casado Connor A. Jacobson Huy Nguyen Bose Kochupurakkal Zoltan Maliga Clarence Yapp Yu-An Chen Denis Schapiro Yinghui Zhou Julie R. Graham Bruce J. Dezube Pamela Munster Sandro Santagata Elizabeth Garcia Scott Rodig Ana Lako Dipanjan Chowdhury Geoffrey I. Shapiro Ursula A. Matulonis Peter J. Park Sampsa Hautaniemi Peter K. Sorger Elizabeth M. Swisher Alan D. D’Andrea Panagiotis A. Konstantinopoulos |
| author_sort |
Anniina Färkkilä |
| title |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer |
| title_short |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer |
| title_full |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer |
| title_fullStr |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer |
| title_full_unstemmed |
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer |
| title_sort |
immunogenomic profiling determines responses to combined parp and pd-1 inhibition in ovarian cancer |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2020-03-01 |
| description |
A Phase I/II trial previously revealed variable anti-tumor efficacy of the PARP inhibitor niraparib in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here, the authors perform an integrated genomic and immunomics analysis of tumor samples from the same patients and find potential predictive biomarkers of response to such combination therapy. |
| url |
https://doi.org/10.1038/s41467-020-15315-8 |
| work_keys_str_mv |
AT anniinafarkkila immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT dogacgulhan immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT juliacasado immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT connorajacobson immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT huynguyen immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT bosekochupurakkal immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT zoltanmaliga immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT clarenceyapp immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT yuanchen immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT denisschapiro immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT yinghuizhou immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT juliergraham immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT brucejdezube immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT pamelamunster immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT sandrosantagata immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT elizabethgarcia immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT scottrodig immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT analako immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT dipanjanchowdhury immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT geoffreyishapiro immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT ursulaamatulonis immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT peterjpark immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT sampsahautaniemi immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT peterksorger immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT elizabethmswisher immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT alanddandrea immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer AT panagiotisakonstantinopoulos immunogenomicprofilingdeterminesresponsestocombinedparpandpd1inhibitioninovariancancer |
| _version_ |
1721451198346690560 |